Diabetes mellitus (DM) is a common chronic medical problem worldwide; one of its complications is painful peripheral neuropathy, which can substantially erode quality of life and increase the cost of management. Despite its clinical importance, the pathogenesis of painful diabetic neuropathy (PDN) is complex and incompletely understood. Voltage-gated sodium channels (VGSCs) link many physiological processes to electrical activity by controlling action potentials in all types of excitable cells. Two isoforms of VGSCs, NaV1.3 and NaV1.7, which are encoded by the sodium voltage-gated channel alpha subunit 3 and 9 (Scn3A and Scn9A) genes, respectively, have been identified in both peripheral nociceptive neurons of dorsal root ganglion (DRG) and pancreatic islet cells. Recent advances in our understanding of tetrodotoxin-sensitive (TTX-S) sodium channels NaV1.3 and NaV1.7 lead to the rational doubt about the cause–effect relation between diabetes and painful neuropathy. In this review, we summarize the roles of NaV1.3 and NaV1.7 in islet cells and DRG neurons, discuss the link between DM and painful neuropathy, and present a model, which may provide a starting point for further studies aimed at identifying the mechanisms underlying diabetes and painful neuropathy.
Introduction This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and < 60 years. Methods This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg. Patients were categorized into two groups (≥ 60 and < 60 years). Efficacy outcomes (change in glycated hemoglobin [HbA1c], fasting blood glucose [FBG], and weight; percentage of patients achieving HbA1c target [< 7.0%]) and safety outcomes (incidence of hypoglycemia and gastrointestinal treatment-emergent adverse events [GI TEAEs]) at 26 weeks were evaluated for each age group in both trials. Results A total of 766 patients (≥ 60 years, n = 222; < 60 years, n = 544) were included in the study. A similar reduction of HbA1c was observed in both age groups: AWARD-CHN1, 1.5 mg (least squares mean [LSM] 95% confidence interval [CI] ≥ 60 years: − 1.45% [− 1.69, − 1.21%] and < 60 years: − 1.43% [− 1.59, − 1.28%]) and 0.75 mg (≥ 60 years: − 1.29% [− 1.53, − 1.05%] and < 60 years: − 1.18% [− 1.33, − 1.03%]); AWARD-CHN2, 1.5 mg (≥ 60 years: − 1.60% [− 1.83, − 1.36%] and < 60 years: − 1.64% [− 1.80, − 1.49%]) and 0.75 mg (≥ 60 years: − 1.31% [− 1.55, − 1.08%] and < 60 years: − 1.33% [− 1.48, − 1.17%]). Dulaglutide showed a reduction in HbA1c as early as 4 weeks after initiation of treatment, which was maintained over 26 weeks in both age groups. The percentage of patients achieving HbA1c target < 7.0% at 26 weeks was also similar in both age groups. Incidence of hypoglycemia and GI TEAEs was low in each age group. Conclusion Treatment with once-weekly dulaglutide improved glycemic control in patients with T2D aged ≥ 60 years and < 60 years and was well tolerated in older patients, suggesting it can be considered a safe and effective treatment option for use in older patients with T2D. Trial registration AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582).
Introduction The efficacy and safety of vildagliptin alone or with metformin is well established by randomized trials, but it is unknown whether it can be extrapolated to the real-world setting in Chinese patients with type 2 diabetes mellitus (T2DM). This study aimed to assess the effectiveness and safety of vildagliptin add-on to metformin versus dual oral antidiabetes drug (OAD), non-vildagliptin combination therapies in real-world Chinese patients with T2DM. Methods The China Prospective Diabetes Study was a post-marketing, prospective, multicenter, observational, real-world study conducted in 52 centers. Patients inadequately controlled with OAD monotherapy and who initiated vildagliptin add-on to metformin (VM cohort) or two OADs other than vildagliptin (comparator cohort) were included for the present analysis. The composite primary endpoint was glycated hemoglobin (HbA1c) < 7% and without tolerability events (hypoglycemia, weight gain ≥ 3%, or discontinuation due to gastrointestinal events) at 12 months. Secondary endpoints included change in HbA1c from baseline, subgroup analysis, and tolerability. Propensity score matching analysis was performed to adjust for baseline covariates imbalance (body mass index (BMI) and HbA1c). Results A total of 604 patients received VM and 670 received comparator therapy. Patients who received VM were younger, more obese, and had a higher baseline HbA1c and a shorter duration of T2DM. After propensity score matching, there were 530 patients per cohort. After 12-month treatment, the success rates of the composite primary endpoint were 50.9% and 33.0% in the VM and comparator cohorts, respectively (P < 0.001; odds ratio = 2.10, 95% confidence interval (CI) 1.64–2.70). Furthermore, the success rates of the composite endpoint were higher with VM across geographic area, BMI, and baseline HbA1c subgroups. Fewer tolerability events occurred in the VM cohort versus the comparator cohort (8.3% vs. 16.2%, P < 0.001; relative risk = 0.51, 95% CI 0.36–0.72). Conclusion Compared with dual OAD non-vildagliptin combination therapies, vildagliptin add-on to metformin is effective and safe to achieve glycemic control in Chinese patients with T2DM. Funding Novartis.
Objective: Even when diabetes remission is achieved and maintained through weight loss, relapse is likely if body weight and consequently BMI increase again. This study aims to evaluate the maintenance of remission without ongoing intervention among participants who achieved diabetes remission and normal BMI through intermittent energy restriction. Research design and methods: This study was a randomized controlled trial with parallel-design and open-label. The intervention group received a three-month Chinese Medical Nutrition Therapy (CMNT) diet intervention consisting of six 15-day cycles. Each cycle encompassed five consecutive days of energy restriction (840 kcal/day), succeeded by 10 days of ad libitum eating. During the ad libitum dietary phase and the subsequent 3-year follow-up, participants self-selected food according to the Chinese Dietary Guidelines for Diabetes (2017 edition). Eventually, their HbA1c, fasting blood glucose (FBG), antidiabetic medication use, weight, quality of life, and complications were assessed. Results: After 3 years of follow-up, 75% of participants in the CMNT group maintained diabetes remission compared to none in the control group. The maintenance of remission was found to be positively correlated with the extent of withdrawal of insulin or insulinotropic agent through the intervention. However, for people whose BMI is below 24 kg/m², regaining weight did not affect the maintenance of remission. Additionally, the CMNT group exhibited significant improvements in quality of life, along with lower rates of complications, hospitalizations, and all-cause mortality. Conclusion: For individuals with normal BMI, after following a three-month CMNT, diabetes remission is observed over three years without ongoing structured maintenance. Clinical Trial Registry: chictr.org.cn , identifier ChiCTR2000038036.